Altering the membership of the Prescription Drug Affordability Stakeholder Council; requiring the Prescription Drug Affordability Board, under certain circumstances, to establish a process for setting upper payment limits for purchases and payor reimbursements of prescription drug products that the Board determines have led or will lead to affordability challenges; authorizing the Board to reconsider an upper payment limit for a drug that becomes a current shortage; and altering requirements related to the setting of upper payment limits.